New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices - Episode 3

Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies

, , ,

An examination of results from key studies in the DLBCL landscape are conducted by Dr Fred Locke.

EP. 1: Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning
EP. 2: Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices
Now Viewing
EP. 3: Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies
EP. 4: Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population
EP. 5: Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study
EP. 6: Panel Discuses Use of CD19 Bispecifics in Sequencing
EP. 7: Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion
EP. 8: Current Approach to Bridging Therapy in R/R DLBCL
EP. 9: Risk of Secondary Malignancies in Heavily Pre-Treated Population
EP. 10: Management of CRS and ICANS with CAR T-cell Therapy
EP. 11: Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line
EP. 12: Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy
EP. 13: Bispecific therapy – treatment setting and management of short-term adverse events
EP. 14: Bispecific therapy – management of long-term adverse events in the community setting
EP. 15: Practice Patterns and Real Use of Epcoritamab and Glofitamab
EP. 16: Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

Video content above is prompted by the following:

  • Please discuss the data supporting CAR T-cell therapy as the primary 2Ltreatment option for patients who are transplant-eligible and have primary refractory or early relapse R/R DLBCL.
    • Please review the latest 56-month follow-up data of the ZUMA-7study, evaluating axi-cel.
      • ASH 2024 Update: Subgroup Analysis of the ZUMA-7 study.
      • Please discuss the subsequent cellular immunotherapy off-protocol in the SOC arm.
  • Please review the 36-month follow-up data of the TRANSFORM study, evaluating liso-cel.
    • ASCO 2024 Update: Subgroup analysis of the TRANSFORM study [primary refractory vs. early relapsed].
  • What were some key takeaways from the results of these two studies?